• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Tela Bio wins FDA nod for OviTex hernia repair bioscaffold

Tela Bio wins FDA nod for OviTex hernia repair bioscaffold

July 14, 2016 By Fink Densford

Tela BioSurgical reconstruction company Tela Bio said yesterday it won FDA 510(k) clearance for its Ovitex portfolio of ventral hernia repair and abdominal wall construction reinforced bioscaffold products.

The Malvern, Penn.-based company said it is launching the portfolio of devices in the U.S. upon receiving clearance from the federal watchdog.

“We are committed to collaborating closely with leading surgeons to reinvigorate the soft tissue reconstruction implant market and bring high performance, cost-effective solutions to hospitals, surgeons and patients. Surgeons have been telling us that integrating polymer and biologic materials represented a necessary evolution in hernia repair that minimizes the amount of foreign material left behind and provides the promise of a durable repair.  We have developed an extensive pre-clinical research data set to support our products. These data have consistently demonstrated important performance advantages over commercially available biologic and synthetic materials,” CEO Antony Koblish said in a press release.

The OviTex RBS devices are designed for soft tissue repair, and are designed from an embedded polymer and intact extracellular matrix.

“Without an ideal surgical mesh implant, over the last decade many surgeons have focused on learning novel hernia repair techniques to accommodate for older technology implants. The reinforced technology in the OviTex portfolio combines the strength advantages of synthetics with a natural biologic material, offering the best of both worlds and helping surgeons achieve successful patient outcomes without the need to learn new techniques,” Dr. Stephen Ferzoco said in prepared remarks.

Tela Bio’s portfolio is composed of 6 products in various sizes, thicknesses and different degrees of reinforcement to allow for appropriate selection dependant upon procedure and surgical technique required.

Filed Under: 510(k), Business/Financial News, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Tela Bio

More recent news

  • Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict
  • RadNet closes iCAD acquisition, expands AI breast‑imaging portfolio
  • Hyperfine reports first commercial sales of next-gen AI-powered Swoop
  • Stereotaxis announces $12.5M offering
  • Nuwellis ends clinical trial of its ultrafiltration tech for heart failure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy